Schoenberg Mark 4

What Happened
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), had 10,000 restricted stock units (RSUs) convert to ordinary shares on 2026-06-08. Immediately following the vesting/conversion, he sold 5,222 shares in an open-market transaction at $27.30 per share, generating $142,561 in proceeds. The filing also records the RSU conversion/derivative disposition tied to that settlement.

Key Details

• Transaction date: 2026-06-08; Form 4 filed: 2026-06-09 (timely filing). Accession: 0001437749-26-019964.
• Converted/received: 10,000 shares via RSU settlement (reported as derivative conversion, code M).
• Sold: 5,222 shares at $27.30 each for $142,561 (open-market sale, code S).
• A parallel derivative disposition (10,000 shares at $0.00) is reported to reflect RSU settlement/termination.
• Reason for sale: tax withholding upon RSU settlement (footnote confirms shares sold to satisfy withholding).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• These transactions reflect the scheduled vesting and settlement of RSUs granted on June 8, 2023 (30,000 RSUs total, vesting in three equal annual installments beginning June 8, 2024).
• The sale appears to be a routine sale to cover tax-withholding obligations on vested RSUs, not a discretionary open-market sale for investment purposes.
• Derivative entries (code M) here indicate conversion/settlement of RSUs into ordinary shares; one sale (code S) represents the portion sold to satisfy taxes.